Bristol Myers faces renewed, $6.7 billion lawsuit over delayed cancer drug
Bristol Myers Squibb was hit on Thursday with a $6.7 billion lawsuit claiming it cheated former Celgene shareholders by ...
Bristol Myers faces renewed, $6.7 bln lawsuit over delayed cancer drug
Bristol Myers Squibb was hit on Thursday with a $6.7 billion lawsuit claiming it cheated former Celgene shareholders by ...
Checkpoint Therapeutics: Preparing For Cosibelimab's Upcoming PDUFA Date
Checkpoint Therapeutics' cosibelimab shows strong efficacy in treating cSCC. Learn why CKPT stock could see significant gains ...
Bristol-Myers Squibb Company's (NYSE:BMY) high institutional ownership speaks for itself as stock continues to impress, up 5.7% over last week
Key Insights Significantly high institutional ownership implies Bristol-Myers Squibb's stock price is sensitive ...
Hosted on MSN12h
2 Beaten-Down Dividend Stocks to Buy and Hold
The forward yield is currently 4.8%, while the company has raised its payouts by 90% in the past 10 years. It might be facing ...
FierceBiotech15h
Allogene abandons leukemia plans for CAR-T in wake of Breyanzi approval
Allogene Therapeutics has dropped plans to target one of its allogeneic CAR-Ts at leukemia in the face of competition from ...